Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Neurosci Res ; 91(9): 1183-90, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23825043

RESUMO

Lanthionine ketimine (LK) is a natural sulfur amino acid metabolite with potent neurotrophic activity. Proteomics indicate that LK interacts with collapsin response mediator protein-2 (CRMP2/DPYSL2/UNC-33), a brain-enriched protein that was shown to regulate cytoskeletal remodeling, neuronal morphology, and synaptic function. To elucidate further the molecular interplay and biological action of LK and UNC-33, we began examining the nervous system of Caenorhabditis elegans nematodes in which both LK concentrations and UNC-33 protein were manipulated. To this end, a cell-permeable LK-ester (LKE) was administered to developing C. elegans engineered to express yellow fluorescent protein (YFP) in cholinergic neurons (strain RM3128) or green fluorescent protein (GFP) in GABAergic neurons (strain CZ1200), and neural morphology was assessed. Fluorescent imaging analyses show that LKE exposure to wild-type animals induced neural commissure outgrowth, crossing over, and bundling in both neurites from GABAergic and cholinergic motor neurons. Additionally, when unc-33(e204) hypomorph mutant nematodes (D389N substitution mutants) were exposed to LKE, both the neuroanatomical defects of incomplete dorsoventral neural commissures and the ventral nerve cord gaps were partially rescued. In contrast, LKE did not rescue ventral nerve cord gaps found in unc-33(mn407) null mutant. Together these data suggest possible functions for LK as a regulator of neuritic elongation, corroborate roles for UNC-33/CRMP2 in the mechanism of LKE activity, and suggest the potential of LKE as a therapeutic molecule for neurological diseases involving CRMP2 dysfunction.


Assuntos
Aminoácidos Sulfúricos/uso terapêutico , Encefalopatias/tratamento farmacológico , Proteínas de Caenorhabditis elegans/genética , Deficiências do Desenvolvimento/tratamento farmacológico , Mutação/genética , Fatores de Crescimento Neural/genética , Fármacos Neuroprotetores/uso terapêutico , Fatores Etários , Aminoácidos Sulfúricos/química , Aminoácidos Sulfúricos/farmacologia , Análise de Variância , Animais , Animais Geneticamente Modificados , Proteínas de Bactérias/genética , Encefalopatias/complicações , Encefalopatias/genética , Caenorhabditis elegans , Deficiências do Desenvolvimento/complicações , Deficiências do Desenvolvimento/genética , Modelos Animais de Doenças , Neurônios GABAérgicos/efeitos dos fármacos , Neurônios GABAérgicos/patologia , Locomoção/efeitos dos fármacos , Locomoção/genética , Longevidade/efeitos dos fármacos , Longevidade/genética , Proteínas Luminescentes/genética , Sistema Nervoso/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...